Explicyte is proud to announce that it is the first immuno-oncology CRO in Europe equipped with the 10x Genomics Xenium platform for single-cell spatial transcriptomics.
Training by the 10x Genomics team has started, marking an important milestone in the expansion of Explicyte’s spatial biology and translational immuno-oncology capabilities.
A New Era for Translational Research and Biomarker Discovery
“For our translational and data science team, the Xenium platform opens unexplored avenues for analyzing tumors and their microenvironment in response to various cancer modalities, including immunotherapies.
For our sponsors, gaining a deep understanding of the gene expression profiles and spatial distribution of individual cells within a tumor specimen can provide unique insights into understanding tumor biology, and mechanisms at play in anti-cancer response or resistance to treatment. It creates opportunities to identify new targets and biomarkers to predict clinical outcomes for cancer patients.
As a researcher, I’m eager to watch tumor cells, immune cells, cancer-associated fibroblasts with the Xenium eye, and to witness the single-cell architecture of immune infiltrates and tertiary lymphoid structures. We are truly excited as we enter a new era of cancer discovery.”
Alban Bessede, CEO of Explicyte Immuno-Oncology
About the 10x Xenium Platform
The 10x Xenium platform brings single-cell spatial transcriptomics capabilities to standard tumor specimens and enables the visualization of tumor microenvironment architecture at subcellular resolution.
- Compatible with standard tumor specimens, including frozen and FFPE samples
- Visualization of tumor microenvironment architecture at subcellular level with a 5,000-gene panel
- Single-cell analysis and segmentation supported by AI-driven algorithms
Strengthening Explicyte’s Spatial Biology Platform
With the integration of the Xenium platform, Explicyte further strengthens its position as a specialized immuno-oncology CRO supporting target identification, biomarker discovery, and translational research programs.
This new capability complements Explicyte’s existing expertise in digital pathology (IF/IHC), spatial transcriptomics, single-cell analysis, and multiparametric biomarker profiling.
By combining advanced tissue-based technologies with dedicated immuno-oncology and data science expertise, Explicyte continues to support sponsors in generating deeper insights into tumor biology and therapeutic response.
Learn more about our services for target identification and
biomarker discovery in immuno-oncology.